



## Corrigendum

# Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’ [Eur J Cancer, 119 (September 2019) Pages 30–34]



Wiebke Sondermann <sup>a,1</sup>, Jochen Sven Utikal <sup>b,c,1</sup>, Alexander H. Enk <sup>d</sup>, Dirk Schadendorf <sup>a</sup>, Joachim Klode <sup>a</sup>, Axel Hauschild <sup>e</sup>, Michael Weichenthal <sup>e</sup>, Lars E. French <sup>f</sup>, Carola Berking <sup>g</sup>, Bastian Schilling <sup>h</sup>, Sebastian Haferkamp <sup>i</sup>, Stefan Fröhling <sup>j</sup>, Christof von Kalle <sup>j</sup>, Titus J. Brinker <sup>d,j,\*</sup>

<sup>a</sup> Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

<sup>b</sup> Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany

<sup>c</sup> Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany

<sup>d</sup> Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany

<sup>e</sup> Department of Dermatology, University Hospital Kiel, University of Kiel, Kiel, Germany

<sup>f</sup> Department of Dermatology, University Hospital Munich (LMU), Munich, Germany

<sup>g</sup> Department of Dermatology, University Hospital Erlangen, University of Erlangen, Erlangen, Germany

<sup>h</sup> Department of Dermatology, University Hospital Würzburg, University of Würzburg, Germany

<sup>i</sup> Department of Dermatology, University Hospital Regensburg, Regensburg, Germany

<sup>j</sup> National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

Dr. Titus J. Brinker regrets that he originally forgot to disclose the following potential conflict of interest:

Dr. Brinker owns a company that develops mobile apps (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg). Dr. Brinker asked for this corrigendum himself for the reason that a

paragraph of this perspective article discusses mole monitoring apps. No third party was involved in instructing this corrigendum.

Dr. Brinker would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2019.07.009>.

\* Corresponding author: National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. Fax: +496221 566967.

E-mail address: [titus.brinker@nct-heidelberg.de](mailto:titus.brinker@nct-heidelberg.de) (T.J. Brinker).

<sup>1</sup> These authors contributed equally to this work.

<https://doi.org/10.1016/j.ejca.2019.10.003>

0959-8049/© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).